Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Altman

Showing results (361-370 of 365) with videos related to

Pageof 37
Sort By:
You have reached the last page of results.This site can display upto 365 results.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026Daniel A Pollyea, Jessica K Altman, Rita Assi, et al.
The New England Journal of Medicine|September 10, 2015
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaEnrico Tiacci, Jae H Park, Luca De Carolis, et al.
The New England Journal of Medicine|June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
The Lancet. Haematology|August 12, 2023
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international expertsRory M Shallis, Naval Daver, Jessica K Altman, et al.
The Journal of Clinical Investigation|December 30, 2025
Mutant p53 promotes clonal hematopoiesis through generating a chronic inflammatory microenvironmentSisi Chen, Sergio Barajas, Sasidhar Vemula, et al.
Pageof 37

Showing results (361-370 of 365) with videos related to

Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 365 results.
Journal of the National Comprehensive Cancer Network : JNCCN|June 15, 2026
NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026Daniel A Pollyea, Jessica K Altman, Rita Assi, et al.
The New England Journal of Medicine|September 10, 2015
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell LeukemiaEnrico Tiacci, Jae H Park, Luca De Carolis, et al.
The New England Journal of Medicine|June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
The Lancet. Haematology|August 12, 2023
Standardising acute myeloid leukaemia classification systems: a perspective from a panel of international expertsRory M Shallis, Naval Daver, Jessica K Altman, et al.
The Journal of Clinical Investigation|December 30, 2025
Mutant p53 promotes clonal hematopoiesis through generating a chronic inflammatory microenvironmentSisi Chen, Sergio Barajas, Sasidhar Vemula, et al.
Pageof 37